Skip to main content

Essential website updates between 07:00-07:15am CET 22 November 2024 may cause disruption.

Country Hub

  • Country portal | COVAX platform

Secondary nav

  • Gavi's next strategic period
  • #ForOurFuture
  • Ethics Hotline

Donate

  • #Forourfuture
  • Donate
  • EN
  • FR
Home

Main navigation

Menu
  • Our Alliance
    Our Alliance
    • About
    • Strategy
      • Vaccine Investment Strategy 2024
      • Phase 6 (2026–2030)
      • Phase 5 (2021–2025)
        • The equity goal
        • The healthy markets goal
        • The sustainability goal
        • The vaccine goal
      • Phase 4 (2016–2020)
        • The market shaping goal
        • The sustainability goal
        • The systems goal
        • The vaccine goal
      • Phase 3 (2011–2015)
        • The financing goal
        • The health systems goal
        • The market shaping goal
        • The vaccine goal
      • Phase 2 (2006–2010)
      • Phase 1 (2000–2005)
      • Risk management
      • Learning System Strategy
      • Gender and immunisation
    • Operating model
      • Gavi's partnership model
        • The Bill & Melinda Gates Foundation
        • UNICEF
        • WHO
        • The World Bank Group
        • Civil society: driving increased equity in immunisation
        • Developing country governments
        • Developing country pharmaceutical industry
        • Industrialised country governments
        • Industralised country pharmaceutical industry
        • Research and technical institutes
      • Gavi's business model
      • Gavi Secretariat
      • Gavi transparency portal and IATI
    • Governance
      • Gavi Board
        • Board Committees
        • Board composition
        • Board members
        • Board and Committee minutes
        • Calendar
      • Governance and legal structures
      • Corporate Policies
      • Audit and Investigations
    • Market Shaping
      • Vaccine Innovation Prioritisation Strategy
      • Market Shaping roadmaps
      • Product information for vaccines and cold chain equipment
      • Vaccine demand forecasting
    • Global health and development
      • Decade of Vaccines Collaboration
      • International Health Partnership for UHC 2030
      • Millennium Development Goals
      • Sustainable Development Goals
      • UN Global Strategy for Women's, Children's and Adolescents' Health
      • Climate, health and immunisation
      • Global health security
    • Work with us
      • Culture
      • Health equity and human rights
      • Vacancies
      • Internship programme
      • RFPs, EOIs and consulting opportunities

    Gavi is an international organisation bringing together public and private sectors with the shared goal of saving lives and protecting people’s health by increasing equitable and sustainable use of vaccines.

    Learn more

    FOCUS AREAS African Vaccine Manufacturing Accelerator (AVMA) Zero-Dose Child Gavi Secretariat and leadership Progress report Partners Our Board

    CAREERS Current vacancies Internship programme RFPs and consulting

    Contact us ISO certification Phishing and fraud

  • Programmes & Impact
    Programmes & Impact
    • How our support works
      • Gavi Support Guidelines
      • Independent Review Committee
      • Joint appraisals
      • Country portal and COVAX collaboration platform
    • Types of support
      • Gavi funding for civil society organisations
      • Vaccine support
        • COVID-19 vaccines
        • Human papillomavirus
        • Inactivated polio vaccine
        • Japanese encephalitis
        • Measles and measles-rubella
        • Meningitis A
        • Oral cholera
        • Pentavalent
        • Pneumococcal
        • Rotavirus
        • Typhoid
        • Yellow fever
      • Health system and immunisation strengthening
        • Immunisation supply chain
        • Data
        • Leadership, management and coordination
        • Learning and Performance Management (LPM)
        • Demand promotion
      • Partners' Engagement Framework
        • Targeted country assistance
        • Strategic focus areas
        • Foundational support
      • Making immunisation sustainable
        • Eligibility
        • Gavi’s approach to engaging with middle-income countries
        • Co-financing
      • Regional manufacturing strategy
        • African Vaccine Manufacturing Accelerator (AVMA)
        • Vaccine markets dashboard
    • Country Hub
      • Africa
        • Angola
        • Benin
        • Burkina Faso
        • Burundi
        • Cameroon
        • Central African Republic (the)
        • Chad
        • Comoros
        • Congo
        • Congo, DR
        • Côte d’Ivoire
        • Eritrea
        • Ethiopia
        • Gambia
        • Ghana
        • Guinea
        • Guinea-Bissau
        • Kenya
        • Lesotho
        • Liberia
        • Madagascar
        • Malawi
        • Mali
        • Mauritania
        • Mozambique
        • Niger
        • Nigeria
        • Rwanda
        • Sao Tome and Principe
        • Senegal
        • Sierra Leone
        • South Sudan
        • Tanzania, UR
        • Togo
        • Uganda
        • Zambia
        • Zimbabwe
      • Americas
        • Bolivia
        • Cuba
        • Guyana
        • Haiti
        • Honduras
        • Nicaragua
      • Eastern Mediterranean
        • Afghanistan
        • Djibouti
        • Pakistan
        • Somalia
        • Sudan
        • Yemen
      • Europe
        • Albania
        • Armenia
        • Azerbaijan
        • Bosnia & Herzegovina
        • Georgia
        • Kyrgyzstan
        • Moldova
        • Tajikistan
        • Turkmenistan
        • Ukraine
        • Uzbekistan
      • South-East Asia
        • Bangladesh
        • Bhutan
        • India
        • Indonesia
        • Korea, DPR
        • Myanmar
        • Nepal
        • Sri Lanka
        • Timor Leste
      • Western Pacific
        • Cambodia
        • China
        • Kiribati
        • Lao PDR
        • Mongolia
        • Papua New Guinea
        • Solomon islands
        • Vietnam
    • Our impact
      • Digital health information (DHI)
      • Measuring our performance
        • 2011–2015 indicators
        • 2016–2020 indicators
        • 2021–2025 indicators
      • Countries approved for support
      • Evaluation studies
      • Facts and figures
      • Progress reports
    • Programmatic policies
      • Co-financing policy
      • Fragility, emergencies and displaced populations policy
      • Gender policy
      • Health system and immunisation strengthening policy
      • Prioritisation mechanism
      • Risk policy
      • Self-procurement policy
      • Transparency and accountability
      • Vaccine donation policy

    SUPPORTED COUNTRIESSupported countriesDetailed information on each Gavi-eligible country

    Explore our Country Hub

    FOR COUNTRIES

    Apply for support

    Gavi 5.0 Ceilings by country and support type

     

    OUR RESULTS

    Evaluation studies

    Facts and figures

    Progress reports

    African Vaccine Manufacturing Accelerator (AVMA)

    COVID-19

  • Investing in Gavi
    Investing in Gavi
    • Resource mobilisation process
      • #ForOurFuture: Gavi’s Investment Opportunity 2026-2030
      • The Gavi COVAX AMC 2022 Investment Opportunity
      • Gavi COVAX AMC Summit 2021
      • Raising Generation immUnity: Global vaccine impact conference
      • Gavi COVAX AMC Investment Opportunity 2021 Launch Event
      • Global Vaccine Summit 2020
      • Previous events
        • Gavi's Investment Opportunity launch meeting, 30 August 2019
        • Gavi Mid-Term Review, Abu Dhabi high level conference, 10-11 December 2018
        • Gavi pledging conference January 2015
        • Gavi replenishment launch meeting May 2014
        • Gavi Mid-Term Review meeting October 2013
        • Gavi pledging conference June 2011
        • Call for Action and Resources October 2010
        • Financing Country Demand March 2010
    • Funding
      • Overview 2000–2037
      • Current period 2021–2025
      • Donor profiles
        • AerCap Ireland Limited
        • Children’s Investment Fund Foundation (CIFF)
        • Croda Foundation
        • Eleanor Crook Foundation
        • Integrate Health
        • KSrelief
        • Omnicom
        • Power of Nutrition
        • Scotland
        • The Church of Jesus Christ of Latter-day Saints
        • Airtel Nigeria
        • Al Ansari Exchange
        • Alight Solutions
        • Alwaleed Philanthropies
        • Analog Devices Foundation
        • Arm Limited
        • Asia Philanthropy Circle (APC)
        • Audacious Alliance
        • Australia
        • Austria
        • Bahrain
        • Belgium
        • Bhutan
        • The Bill & Melinda Gates Foundation
        • Blackberry
        • Brazil
        • Burkina Faso
        • Cameroon
        • Canada
        • Centene Charitable Foundation
        • China
        • Cisco
        • Coca-Cola Foundation
        • CODE (RED) Campaign
        • Collins Aerospace (Goodrich Corporation)
        • Colombia
        • Croatia
        • Denmark
        • Dolby Laboratories Charitable Fund
        • ELMA Vaccines & Immunization Foundation
        • Epiroc AB
        • Estonia
        • Etsy
        • European Commission
        • Finland
        • France
        • Germany
        • Girl Effect
        • Google.org
        • Greece
        • HH Sheikh Mohammed bin Zayed Al Nahyan
        • Iceland
        • India
        • International Federation of Pharmaceutical Wholesalers
        • Ireland
        • Italy
        • Japan
        • Gamers Without Borders
        • Kuwait
        • ”la Caixa” Foundation
        • Laerdal
        • Liechtenstein
        • Luxembourg
        • Malaysia
        • Malta
        • Mastercard
        • Mauritius
        • McHugh O'Donovan Foundation
        • Mexico
        • Monaco
        • Netherlands
        • New Zealand
        • Niger
        • Norway
        • Oman
        • Orange
        • Other private donors
        • Pager Duty
        • Philippines
        • Poland
        • Portugal
        • Pratt & Whitney
        • Proctor & Gamble
        • Qatar
        • Reed Hastings and Patty Quillin
        • Republic of Korea
        • Republic of Moldova
        • Rockefeller Foundation
        • Russell Reynolds Associates
        • Russian Federation
        • Salesforce
        • Saudi Arabia
        • Shell International
        • Singapore
        • Slovenia
        • SMBC Aviation Capital Limited
        • South Africa
        • Spain
        • Spotify
        • Stanley Black & Decker
        • Sweden
        • Switzerland
        • SymAsia Foundation
        • Thistledown Foundation
        • TikTok
        • Toyota Tsusho
        • Twilio
        • Uganda
        • UBS Optimus Foundation
        • Unilever
        • United Kingdom
        • United States of America
        • UPS
        • Vaccine Forward Initiative
        • Viet Nam
        • The Visa Foundation
        • WHO Foundation-Go Give One Campaign
        • Wise
        • Workday Foundation
    • Partnering with business
    • Innovative financing
      • IFFIm
      • Pneumococcal AMC
        • About the pneumococcal AMC
        • How it works
        • Manufacturers
        • How countries can apply
        • Timeline
        • Independent Assessment Committee
        • AMC legal agreements
      • Gavi Matching Fund
      • Loan buydown
    • INFUSE
      • INFUSE community
      • Call for innovations

    #FOROURFUTURE

    Five years to save 8 million lives: everything you need to know about Gavi’s Investment Opportunity

    Five years to save 8 million lives: everything you need to know about Gavi’s Investment Opportunity


    Read article

    KEY AREAS

    Donor profiles

    Matching Fund

    Pneumococcal AMC

    African Vaccine Manufacturing Accelerator (AVMA)

  • VaccinesWork
    VaccinesWork
    • About VaccinesWork
    • The science behind COVID-19
    • Emerging threats
    • Tales from the past
    • News from the lab
    • Stories from the community
    VaccinesWork

    VaccinesWork is an award-winning digital platform hosted by Gavi, the Vaccine Alliance covering news, features and explainers from every corner of global health and immunisation.

    SPOTLIGHT ON CLIMATE CHANGE

    Gavi/2024/Asad Zaidi


    Learn more

  • News & Resources
    News & Resources
    • Media room
      • News releases
      • Media contacts
      • Leadership biographies
      • Communication toolkits
    • Publications
    • Document library
      • COVAX data brief
      • COVID-19 situation reports
      • Evaluations
      • IRC reports
      • Financial reports
    • Knowledge products

    KEY PUBLICATION

    Download Gavi's Investment Opportunity 2026–2030


    Investment Opportunity 2026–2030
    Download

    LATEST

    Progress report

    News releases

    Communication toolkits

  • The Break COVID Now Summit

  • EN
  • FR
  • Home
  • VaccinesWork
  • COVID-19 Vaccine Manufacturing: DCVMN's contribution to the global scale-up
Medical Manufacturing Laboratory
Back to

COVID-19 Vaccine Manufacturing: DCVMN's contribution to the global scale-up

16 March 2021 – Opinion by Sai D. Prasad, DCVMN President, and Rajinder Suri, DCVMN CEO

Back to

COVID-19 Vaccine Manufacturing: DCVMN's contribution to the global scale-up

16 March 2021 – Opinion by Sai D. Prasad, DCVMN President, and Rajinder Suri, DCVMN CEO

COVID-19
Home

Footer

  • Our Alliance
  • Programmes & impact
  • Investing in Gavi
  • VaccinesWork
  • News & resources

Country Hub

  • Country portal | COVAX platform

Donate

  • #Forourfuture
  • Donate

Footer nav

  • Careers
  • Contact
  • Ethics hotline
  • IFFIm
  • Privacy notice
  • Terms of use
  • Phishing and fraud

© Gavi 2024

  • Gavi LinkedIn
  • Gavi Twitter
  • Gavi Instagram
  • Gavi Facebook
  • Gavi YouTube
  • Gavi TikTok
VSN logoCAF International logo

Our achievements are thanks to the support and expertise of our founding partners